Title:
抗CD20抗体およびPI3キナーゼ選択的阻害剤の組み合わせ
Document Type and Number:
Japanese Patent JP6437441
Kind Code:
B2
Abstract:
Highly effective combinations of a compound of formula A (a PI3Kδ selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3Kδ and/or CD20 mediated diseases and disorderes. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amelioration of hematological malignancies such as leukemia and lymphoma.
Inventors:
Weiss Michael
Miskin harry
Sportery Peter
Vukalanka Swaloup Kay Vs
Miskin harry
Sportery Peter
Vukalanka Swaloup Kay Vs
Application Number:
JP2015540798A
Publication Date:
December 12, 2018
Filing Date:
November 01, 2013
Export Citation:
Assignee:
TG Therapeutics Inc.
Reisen Pharmaceuticals S.A.R.
Laboratore Francais Du Fraction Numan Edebio Technology
Reisen Pharmaceuticals S.A.R.
Laboratore Francais Du Fraction Numan Edebio Technology
International Classes:
A61K39/395; A61K31/519; A61P35/02
Domestic Patent References:
| JP2012510976A | ||||
| JP2010525037A | ||||
| JP2008523793A |
Foreign References:
| WO2011055215A1 |
Other References:
COMPARISON OF CELL LYSIS MEDIATYED BY LFB-R603 (UBLITUXIMAB) WITH THAT MEDIATED BY OFATUMUMAB AGAINST CELLS EXPRESSING LOW LEVELS OF CD20,53rd ASH Annual Meeting,2011年12月13日,URL,http://www.tgtherapeutics.com/ASH2011Poster3913.pdf
Attorney, Agent or Firm:
Patent Service Corporation Patent Office Sykes